Drug intelligence / Profile preview

CB03

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Topical

Overview

CB03 is a small molecule inhibitor of the SARS-CoV-2 Main Protease (Mpro), identified through structure-based virtual screening. It has a molecular weight of approximately 300 Da and exhibits lead-like characteristics, making it an attractive candidate for the future development of COVID-19 treatments. It has shown promising inhibition of the Mpro enzyme with Ki values in the medium to high micromolar range.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on CB03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB03.

Explore the full profile